Skip to content
AnalystLens

Neurocrine Biosciences 8-K Report, Executive Changes (May 23, 2024)

Reports
Leadership Changes·Shareholder Matters
Filing Date
Filed May 23, 2024
Period End
May 22, 2024
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed May 23, 2024. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. filed this Form 8-K on May 23, 2024 to report the results of its 2024 Annual Meeting of Stockholders, held on May 22, 2024.

Stockholders approved an amendment to the Company's 2020 Equity Incentive Plan (the Amended 2020 Plan), and the summary of its material terms is set forth in the definitive proxy statement filed with the SEC on April 10, 2024. Of the 100,580,497 shares of common stock entitled to vote as of the March 25, 2024 record date, 90,166,107 shares were present in person or by proxy. Stockholders voted on four matters.

All four nominees for Class I Director (William H. Rastetter, Ph.D., George J. Morrow, Leslie V.

Norwalk, and Christine A. Poon) were elected to three-year terms expiring at the 2027 Annual Meeting. The advisory vote on named executive officer compensation passed with 80,281,842 votes for and 4,276,395 against.

The Amended 2020 Plan was approved with 76,076,416 votes for and 9,499,523 against. The appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2024 was ratified with 84,641,389 votes for and 5,451,051 against.

For investors, the filing is primarily governance-related and reports no new financial results, transactions, or changes in leadership beyond the director elections. The most notable item is the approval of the Amended 2020 Plan, which the Company describes only by reference to its proxy statement, and the Plan's specific terms are not stated in this filing.

Key Highlights

  1. Annual Meeting held May 22, 2024; 90,166,107 of 100,580,497 eligible shares were present in person or by proxy.
  2. Stockholders approved an amendment to the 2020 Equity Incentive Plan (Amended 2020 Plan) with 76,076,416 votes for and 9,499,523 against.
  3. All four Class I Director nominees were elected to terms expiring at the 2027 Annual Meeting, with William H. Rastetter, Ph.D. receiving 72,381,261 votes for and George J. Morrow receiving 80,403,845.
  4. Advisory say-on-pay vote on named executive officer compensation was approved with 80,281,842 votes for and 4,276,395 against.
  5. Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024, with 84,641,389 votes for and 5,451,051 against.
  6. Class II Directors (Richard F. Pops, Shalini Sharp, Stephen A. Sherwin, M.D.) and Class III Directors (Kevin C. Gorman, Ph.D., Gary A. Lyons, Johanna Mercier) continue in office until the 2025 and 2026 annual meetings, respectively.

Frequently Asked Questions

  1. What did stockholders approve at the 2024 Annual Meeting?

    Stockholders elected four Class I Directors, approved on an advisory basis the compensation of named executive officers, approved the amendment to the 2020 Equity Incentive Plan, and ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2024.

  2. What is the Amended 2020 Plan and where are its terms described?

    The Amended 2020 Plan is an amendment to the Company's 2020 Equity Incentive Plan approved by stockholders. The filing states that a summary of its material terms is set forth in the definitive proxy statement filed on April 10, 2024, which is incorporated by reference.

  3. Was there significant opposition to any of the proposals?

    Opposition was relatively modest across proposals. The Amended 2020 Plan received 9,499,523 votes against, the largest opposing count among the proposals, while the say-on-pay proposal drew 4,276,395 votes against and the auditor ratification drew 5,451,051 votes against. Each proposal was approved.

  4. Does this filing report any new financial results or transactions?

    No. The filing reports only the outcome of the stockholder votes and the incorporation of the proxy statement summary of the Amended 2020 Plan. It does not disclose financial results, acquisitions, or other transactions.